124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy

Tijink, Bernard M.; Perk, Lars R.; Budde, Marianne; Walsum, Marijke Stigter-van; Visser, Gerard W.M.; Kloet, Reina W.; Dinkelborg, Ludger; Leemans, C. René; Neri, Dario; Dongen, Guus A.M.S. van

doi:10.1007/s00259-009-1096-y

Cited by 86 publications

(74 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43). We have recently reported the development of the fully human radiolabeled antibody product 124 I-L19-SIP, which is ideally suited for immuno-PET imaging and dosimetric calculations before therapeutic intervention with 131 I-L19SIP RIT (33). In our view, the combination of the chosen antibody format (SIP), isotope ( 124 I), and detection technique (immuno-PET) offers unique advantages over other existing approaches.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

Poli

Bianchi

Virotta

et al. 2013

Cancer Immunology Research

Self Cite

View full text Add to dashboard Cite

Radioimmunotherapy (RIT) with 131 I-labeled L19SIP (radretumab; a small immunoprotein format antibody directed against the ED-B domain of fibronectin; $80 kDa molecular weight) has been investigated in several clinical trials. Here, we describe the use of immuno-PET imaging with iodine-124 ( 124 I)-labeled L19SIP to predict doses delivered to tumor lesions and healthy organs by a subsequent radretumab RIT in patients with brain metastases from solid cancer. Bone marrow doses were evaluated both during the diagnostic phase and posttherapy, measuring activities in blood (germanium detector) and whole body (lanthanum bromide detector). Expected doses for radretumab administration (4,107 MBq/m 2 ) were calculated from data obtained after administration of an average of 167 MBq 124 I-L19SIP to 6 patients. To assess lesion average doses, the positron emission tomography (PET) scanner was calibrated for the use of 124 I with an International Electrotechnical Commission (IEC) Body Phantom and recovery coefficients were calculated. The average dose to bone red marrow was 0.21 Gy/GBq, with high correlation between provisional and actual posttherapy doses. Although the fraction of injected activity in normal organs was similar in different patients, the antibody uptake in the neoplastic lesions varied by as much as a factor of 60. Immuno-PET with 124 I-labeled L19SIP offers significant advantages over conventional 131 I imaging, in particular accuracy of dosimetric results. Furthermore, the study indicates that antibody uptake can be highly variable even in different lesions of the same patient and that immuno-PET procedures may guide product development with armed antibodies. Cancer Immunol Res; 1(2); 134-43. Ó2013 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Comparative analysis of the L19 antibody in scFv, full immunoglobulin G (IgG), and small immunoprotein (SIP) format identified L19SIP as the preferred format for RIT (27,(31)(32)(33). The molecular weight of L19-SIP in its nonreduced form is approximately 80 kDa.…”

Section: Introductionmentioning

confidence: 99%

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

Poli

Bianchi

Virotta

et al. 2013

Cancer Immunology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast to the situation in oncology, where lesions can be visualized thanks to radio-labeled antibodies [33], the use of immuno-PET procedures for the visualization of atherosclerotic plaques may present challenges in relation both to the size and the body location. While it should be feasible to use PET methodologies to image plaques in the carotid and at branches of the aorta, the visualization of atherosclerosis in coronary arteries is complicated by their small size and by the movement of the heart.…”

Section: Discussionmentioning

confidence: 99%

Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies

Pedretti¹,

Rančić

Soltermann

et al. 2010

Atherosclerosis

Self Cite

View full text Add to dashboard Cite

“…To target the VEGF receptor, probes such as 64 Cu-DOTA-VEGF121 is used where DOTA acts as a chelator [62]. 124-L19-SIP monoclonal antibody was targeted against extra domain-B of fibronectin [63] (as shown in Figure 3). 123 I-L19(scFv)2 targeted towards fibronectin an imaged by SPECT/CT modality [64].…”

Section: Tumor Vasculaturementioning

confidence: 99%

Theranostic Probes for Targeting Tumor Microenvironment: An Overview

Sikkandhar

Nedumaran

Ravichandar

et al. 2017

Preprint

View full text Add to dashboard Cite

Long gone was the time when tumors were thought to be insular masses of cells, residing independently at specific sites in an organ. Now, researchers gradually realize that tumors interact with the extracellular matrix (ECM), blood vessels, connective tissues and immune cells in their environment, which is now known as the tumor microenvironment (TME). It is found that the interactions between tumors and their surrounding promote tumor growth, invasion and metastasis. The dynamics and diversity of TME cause the tumors to be heterogeneous and thus pose a challenge for cancer diagnosis, drug design and therapy. As TME is significant in enhancing tumor progression, it is vital to identify the different components in the TME. This review explores how different factors in the TME supply tumors with the required growth factors and signaling molecules to proliferate, invade and metastasis. We also examine the development of TME-targeted nanotheranostics over the recent years for cancer therapy, diagnosis and anticancer drug delivery system. This review further discusses the limitations and future perspective of nanoparticle based theranostics when used in combination with current imaging modalities like Optical Imaging, Magnetic Resonance Imaging (MRI) and Nuclear Imaging (PET and SPECT).

show abstract

124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy

Abstract: Purpose The human monoclonal antibody (MAb) fragment L19-SIP is directed against extra domain B (ED-B) of fibronectin, a marker of tumour angiogenesis. A clinical radioimmunotherapy (RIT) trial with 131

Cited by 86 publications

References 27 publications

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies

Theranostic Probes for Targeting Tumor Microenvironment: An Overview

Contact Info

Product

Resources

About